The DOI resolves to a real, refereed Nature Biotechnology paper. Its abstract states: the authors compare six proteomic clocks (ProtAge, OrganAge-mortality, OrganAge-chrono, PAC, ipfP3GPT and PAOPAC) on serum proteomes from a published 12-week phase 2a trial of the candidate anti-fibrotic drug rentosertib in idiopathic pulmonary fibrosis, and find that all six clocks consistently predicted lower biological age in treated arms . The abstract also states the limitation the post reproduces: "proteomic clocks alone cannot deconvolute aging- and disease-specific effects."

The authors addressed this indirectly through pathway analyses identifying potential anti-aging shifts in senescence and metabolic processes.

The underlying trial is also real and refereed. The Nature Medicine paper describes a phase 2a multicenter, double-blind, randomized, placebo-controlled trial of rentosertib (formerly ISM001-055), a first-in-class AI-generated small-molecule inhibitor of TNIK, a first-in-class target in IPF discovered using generative AI , with patients randomized to 12 weeks of 30 mg once daily (n=18), 30 mg twice daily (n=18), 60 mg once daily (n=18) or placebo (n=17) , that is 71 patients total across 22 sites in China.

The 42-participant figure comes from the proteomic subset. Insilico reports that researchers evaluated serum proteome profiles from 42 trial participants across 2,841 proteins, applying ProtAge, OrganAge (chronological and mortality variants), PAC, ipfP3GPT and PAOPAC, and that all six clocks showed a trend toward reversed biological age versus placebo, with peak effect at week 4 in participants receiving 30 mg twice daily, approximately 3 to 4 years of reversal and up to 6 years on one clock. Independent coverage describes the same: the analysis used blood samples from a 12-week clinical trial of 42 IPF patients , and all six clocks pointed in the same direction, with the drug changing the trajectories of 326 circulating proteins, lowering those associated with scarring and cellular aging .

Context the post omits is available in the same reporting. Four of the five clock-development teams behind the six models, including Insilico's own ipfP3GPT, are co-authors on the paper; only PAC, developed at the University of Connecticut, sits outside the author list.

The dose response also diverges: the largest improvement in forced vital capacity in the original trial occurred at 60 mg once daily, while the most consistent clock response was at 30 mg twice daily. The same analysis notes the fit quality of the clocks in this cohort, describing a median R² of 0.06 across 42 patients . The Crossref record carries the conflict disclosure: the first author is founder and CEO of Insilico Medicine, and seven further authors are Insilico employees. The first author himself told Fox News that the finding means patients are predicted to be younger using a validated set of aging clocks, and "We don't know what that means yet," adding that the results do not yet prove the drug can reverse aging or extend life, that it is early days and the drug is still investigational .